Results: 2

Figure 1

Figure 1. Participant flow through the phase II huperzine A trial. From: A phase II trial of huperzine A in mild to moderate Alzheimer disease.

A total of 287 subjects were screened for the trial, and 210 were eligible and randomized. The most common reason for screen failure was Mini-Mental State Examination score being too high.

M.S. Rafii, et al. Neurology. 2011 April 19;76(16):1389-1394.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk